Evaxion A/S (EVAX) stock
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.78+0.01 (+0.36%)
Close on Nov 17, 2026Market cap $23.19MP/E –Yield –
Evaxion A/S cash
Cash and short-term investments held at the end of each period.
Evaxion A/S's cash was $14.00M at Jun 30, 2026. For fiscal 2025 it was $23.23M, up 290.4% from the year before. The highest annual figure on record is $32.17M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.23M | +290.4% |
| FY2024 | Dec 31, 2024 | $5.95M | +6.6% |
| FY2023 | Dec 31, 2023 | $5.58M | -57.7% |
| FY2022 | Dec 31, 2022 | $13.18M | -59.0% |
| FY2021 | Dec 31, 2021 | $32.17M | +451.4% |
| FY2020 | Dec 31, 2020 | $5.83M | -39.0% |
| FY2019 | Dec 31, 2019 | $9.56M | +28.6% |
| FY2018 | Dec 31, 2018 | $7.43M | +1488.2% |
| FY2017 | Dec 31, 2017 | $468.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.00M | +75.2% |
| Q4 FY2025 | Dec 31, 2025 | $23.23M | +316.2% |
| Q2 FY2025 | Jun 30, 2025 | $14.75M | +107.2% |
| Q4 FY2024 | Dec 31, 2024 | $5.95M | -54.9% |
| Q2 FY2024 | Jun 30, 2024 | $7.99M | -68.3% |
| Q4 FY2023 | Dec 31, 2023 | $5.58M | -82.2% |
| Q2 FY2023 | Jun 30, 2023 | $7.12M | -77.9% |
| Q4 FY2022 | Dec 31, 2022 | $13.18M | +10.4% |
| Q2 FY2022 | Jun 30, 2022 | $25.25M | +34.3% |
| Q1 FY2022 | Mar 31, 2022 | $31.41M | +16.5% |
| Q4 FY2021 | Dec 31, 2021 | $32.17M | +451.4% |
| Q3 FY2021 | Sep 30, 2021 | $11.94M | +51.7% |
| Q2 FY2021 | Jun 30, 2021 | $18.80M | +360.2% |
| Q1 FY2021 | Mar 31, 2021 | $26.96M | +324.8% |
| Q4 FY2020 | Dec 31, 2020 | $5.83M | -39.0% |
| Q3 FY2020 | Sep 30, 2020 | $7.88M | +5.9% |
| Q2 FY2020 | Jun 30, 2020 | $4.09M | +772.9% |
| Q1 FY2020 | Mar 31, 2020 | $6.35M | – |
| Q4 FY2019 | Dec 31, 2019 | $9.56M | – |
| Q4 FY2018 | Dec 31, 2018 | $7.43M | – |
| Q4 FY2017 | Dec 31, 2017 | $468.00K | – |
See a number that looks wrong?